Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
GALT's Cash to Debt is ranked higher than
99% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. GALT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GALT' s 10-Year Cash to Debt Range
Min: 0.41  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
GALT's Interest Coverage is ranked higher than
98% of the 389 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. GALT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GALT' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -4.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -81.13
GALT's ROE (%) is ranked lower than
92% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. GALT: -81.13 )
Ranked among companies with meaningful ROE (%) only.
GALT' s 10-Year ROE (%) Range
Min: -1658.88  Med: -149.59 Max: -81
Current: -81.13
-1658.88
-81
ROA (%) -54.91
GALT's ROA (%) is ranked lower than
93% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. GALT: -54.91 )
Ranked among companies with meaningful ROA (%) only.
GALT' s 10-Year ROA (%) Range
Min: -1309.12  Med: -119.64 Max: -56.38
Current: -54.91
-1309.12
-56.38
ROC (Joel Greenblatt) (%) -1432114.29
GALT's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. GALT: -1432114.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GALT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -771500  Med: -9426.55 Max: -3076.64
Current: -1432114.29
-771500
-3076.64
EBITDA Growth (3Y)(%) -7.90
GALT's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 492 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. GALT: -7.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GALT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -7.90 Max: 11.5
Current: -7.9
0
11.5
EPS Growth (3Y)(%) -9.70
GALT's EPS Growth (3Y)(%) is ranked lower than
68% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. GALT: -9.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GALT' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.2  Med: -4.60 Max: 35.1
Current: -9.7
-33.2
35.1
» GALT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GALT Guru Trades in

GALT Guru Trades in

Q1 2014

GALT Guru Trades in Q1 2014

George Soros 48,200 sh (New)
» More
Q2 2014

GALT Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.70
GALT's P/B is ranked higher than
55% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. GALT: 2.70 )
Ranked among companies with meaningful P/B only.
GALT' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 457.5
Current: 2.7
0
457.5
Current Ratio 13.98
GALT's Current Ratio is ranked higher than
93% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. GALT: 13.98 )
Ranked among companies with meaningful Current Ratio only.
GALT' s 10-Year Current Ratio Range
Min: 0.2  Med: 3.52 Max: 23.21
Current: 13.98
0.2
23.21
Quick Ratio 13.98
GALT's Quick Ratio is ranked higher than
94% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. GALT: 13.98 )
Ranked among companies with meaningful Quick Ratio only.
GALT' s 10-Year Quick Ratio Range
Min: 0.2  Med: 3.52 Max: 23.21
Current: 13.98
0.2
23.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.65
GALT's Price/Net Cash is ranked higher than
88% of the 178 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.02 vs. GALT: 2.65 )
Ranked among companies with meaningful Price/Net Cash only.
GALT' s 10-Year Price/Net Cash Range
Min: 3.69  Med: 13.17 Max: 221
Current: 2.65
3.69
221
Price/Net Current Asset Value 2.68
GALT's Price/Net Current Asset Value is ranked higher than
83% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. GALT: 2.68 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GALT' s 10-Year Price/Net Current Asset Value Range
Min: 3.73  Med: 14.87 Max: 732
Current: 2.68
3.73
732
Price/Tangible Book 2.68
GALT's Price/Tangible Book is ranked higher than
60% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. GALT: 2.68 )
Ranked among companies with meaningful Price/Tangible Book only.
GALT' s 10-Year Price/Tangible Book Range
Min: 3.73  Med: 14.87 Max: 516
Current: 2.68
3.73
516
Price/Projected FCF 3.27
GALT's Price/Projected FCF is ranked lower than
54% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. GALT: 3.27 )
Ranked among companies with meaningful Price/Projected FCF only.
GALT' s 10-Year Price/Projected FCF Range
Min: 4.41  Med: 5.99 Max: 115.43
Current: 3.27
4.41
115.43
Earnings Yield (Greenblatt) (%) -86.58
GALT's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. GALT: -86.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GALT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -103.57  Med: 0.00 Max: 0
Current: -86.58
-103.57
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PHPN.Germany,
Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include major multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.
» More Articles for NAS:GALT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
GALECTIN THERAPEUTICS INC Financials Aug 21 2015
Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce... Aug 13 2015
Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce... Aug 13 2015
Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial... Aug 10 2015
Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial... Aug 10 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 10 2015
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID® to Monitor... Aug 03 2015
Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of... Jul 15 2015
Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of... Jul 15 2015
Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with... Jun 29 2015
Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with... Jun 29 2015
Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director Jun 03 2015
Galectin Therapeutics to Present at LD Micro Invitational Conference Jun 03 2015
Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director Jun 03 2015
Galectin Therapeutics to Present at LD Micro Invitational Conference May 28 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 27 2015
Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders May 15 2015
Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam May 14 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 14 2015
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update... May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK